Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574053 · ClinicalTrials.gov registry record
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
A clinical trial of Huntington's Disease, sponsored by CHDI Foundation.
- Recruiting
- Registry status
- 35,000
- Enrollment target
- 20
- Study locations
NCT01574053 is a study of Huntington's Disease that is actively recruiting participants, run by CHDI Foundation. The registered enrollment target is 35,000 participants, above the 419-participant average among 8 other Huntington's Disease trials with a reported enrollment target (8253% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01574053, a study of Huntington's Disease, is actively recruiting participants, sponsored by CHDI Foundation.
- RECRUITING
- Registry status
- 35,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Conditions Studied
Study Locations (20)
California
- University of California - Irvine Medical Center - Irvine
- Loma Linda Medical Center - Loma Linda
- University of California - Los Angeles - Los Angeles
- University of California - Davis - Sacramento
- University of California - San Diego - San Diego
- University of California - San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
- Rush University Medical Center - Chicago
- University of Illinois College of Medicine at Rockford - Rockford
Florida
- University of Florida Board of Trustees - Gainesville
- University of Miami - Miami
- University of South Florida, HDSA Center of Excellence at USF - Tampa
Georgia
- Emory University, Wesley Woods Health Center - Atlanta
- Georgia Health Sciences University - Augusta
Alabama
- University of Alabama - Birmingham
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Colorado
- Cenexel Rocky Mountain Clinical Research, LLC - Englewood
Connecticut
- University of Connecticut - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,000 participants |
| Start Date | 2012-07 |
| Est. Completion | 2062-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574053
The ClinicalTrials.gov registry entry for NCT01574053 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 35,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 419-participant average among 8 other Huntington's Disease trials with a reported enrollment target (8253% higher). The listed sponsor is CHDI Foundation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01574053 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT01574053 about?
NCT01574053 is a clinical study titled "Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort". Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into...
What is the current status of trial NCT01574053?
This trial is currently recruiting. The enrollment target is 35,000 participants. The study started on 2012-07. Estimated completion is 2062-01.
What conditions does trial NCT01574053 study?
This clinical trial studies the following conditions: Huntington's Disease.
Who is sponsoring clinical trial NCT01574053?
This trial is sponsored by CHDI Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01574053 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
RECRUITING
-
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
COMPLETED · Phase 2
-
FuRST 2.0 Cognitive Pre-Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.